Takhzyro 150 MG
Ended Awarded
- Contract number
- 36C24526N0234
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $38,098
Award facts
- Contract value 100% obligated
- $38,097.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Brooks, KY 40109, USA
Award details come from SAM.gov/FPDS.
About this award
On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside designation. The procurement was performed at the vendor's location in Brooks, Kentucky, reflecting the critical supply chain role Takeda plays in federal healthcare delivery.
This delivery order is issued under Takeda Pharmaceuticals America Inc.'s comprehensive single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, valued at $131.04 million for the period July 15, 2025, through July 14, 2026. The BPA covers nine specialized pharmaceutical products across multiple therapeutic areas including hereditary angioedema, hemophilia, immune disorders, and rare metabolic conditions. As a Japan-based subsidiary specializing in advanced biopharmaceutical products for federal healthcare entities, Takeda has established itself as a critical supplier to the Department of Veterans Affairs and other federal agencies through streamlined procurement mechanisms that reduce administrative burden while ensuring rapid access to these essential medications for veteran and federal beneficiary populations.
Quick answers
Who was awarded contract 36C24526N0234?
36C24526N0234 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on January 15, 2026.
How much is contract 36C24526N0234 worth?
The government has obligated $38,098 on 36C24526N0234.
Is contract 36C24526N0234 an order under another contract?
Yes. 36C24526N0234 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0234 competed?
The extent of competition for 36C24526N0234 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award